Lack of effect of desglycinamide-arginine-vasopressin (DGAVP) on memory in patients with korsakoff's syndrome. 1983

F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd

The effect of desglycinamide9-[Arg8]-vasopressin (DGAVP) on memory processes was studied in patients with Korsakoff's syndrome. Intranasal treatment with DGAVP for 7 days affected neither attention nor short- and long-term memories. It is suggested that treatment with DGAVP is not indicated for all types of memory disorders, and that the beneficial effect of this treatment may depend on the integrity of certain brain structures.

UI MeSH Term Description Entries
D008297 Male Males
D008568 Memory Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000425 Alcohol Amnestic Disorder A mental disorder associated with chronic ethanol abuse (ALCOHOLISM) and nutritional deficiencies characterized by short term memory loss, confabulations, and disturbances of attention. (Adams et al., Principles of Neurology, 6th ed, p1139) Alcohol-Induced Amnestic Syndrome,Amnestic Psychosis, Alcohol-Induced,Alcohol Amnestic Syndrome,Alcohol-Induced Amnestic Psychosis,Alcohol-Induced Dysmnesic Psychosis,Alcohol-Induced Dysmnesic Syndrome,Alcohol-Induced Persisting Amnestic Disorder,Alcohol Amnestic Disorders,Alcohol Amnestic Syndromes,Alcohol Induced Amnestic Psychosis,Alcohol Induced Amnestic Syndrome,Alcohol Induced Dysmnesic Psychosis,Alcohol Induced Dysmnesic Syndrome,Alcohol Induced Persisting Amnestic Disorder,Alcohol-Induced Amnestic Psychoses,Alcohol-Induced Amnestic Syndromes,Alcohol-Induced Dysmnesic Psychoses,Alcohol-Induced Dysmnesic Syndromes,Amnestic Disorder, Alcohol,Amnestic Psychoses, Alcohol-Induced,Amnestic Psychosis, Alcohol Induced,Amnestic Syndrome, Alcohol-Induced,Amnestic Syndromes, Alcohol-Induced,Dysmnesic Psychoses, Alcohol-Induced,Dysmnesic Psychosis, Alcohol-Induced,Dysmnesic Syndrome, Alcohol-Induced,Dysmnesic Syndromes, Alcohol-Induced,Psychoses, Alcohol-Induced Amnestic,Psychoses, Alcohol-Induced Dysmnesic,Psychosis, Alcohol-Induced Amnestic,Psychosis, Alcohol-Induced Dysmnesic
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin
D001288 Attention Focusing on certain aspects of current experience to the exclusion of others. It is the act of heeding or taking notice or concentrating. Focus of Attention,Selective Attention,Social Attention,Attention Focus,Attention, Selective,Attention, Social,Selective Attentions

Related Publications

F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
January 1985, Neurobiology of aging,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
October 1982, Psychopharmacology bulletin,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
January 2006, Izvestiia Akademii nauk. Seriia biologicheskaia,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
February 1991, Alcoholism, clinical and experimental research,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
January 1985, Progress in neuro-psychopharmacology & biological psychiatry,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
March 1995, Alcohol and alcoholism (Oxford, Oxfordshire),
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
January 1990, Neuropsychobiology,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
August 2005, Bulletin of experimental biology and medicine,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
June 1982, The Journal of endocrinology,
F Laczi, and J M Van Ree, and L Balogh, and A Szász, and T Járdánházy, and A Wágner, and L Gáspár, and Z Valkusz, and I Dobranovics, and J Szilárd
May 1987, Neuroscience letters,
Copied contents to your clipboard!